Business Wire

GRO Network™ Brings Environmental Transparency to Grain Market

Share

Farmer’s Business Network, Inc. (FBNSM), the leading direct-to-farm ag tech platform and farmer network, today launched GRO Network, which provides new technology and services that facilitate the scoring, sourcing, and pricing of Low-Carbon Grain from farm to fork, making environmental transparency in the grain industry a reality now.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005290/en/

GRO Network enables comprehensive environmental transparency, and supports a market for premium, environmentally-scored grain. GRO Network also provides buying intelligence software that directly connects farmers with consumer packaged goods companies, animal feed providers, biofuel makers and the world’s other major grain buyers.

POET, the world’s largest producer of biofuels has joined GRO Network as a key customer in the market for verifiable Low-Carbon Grain.

“Family farms have already invested the time, innovation and sweat-equity to develop the regenerative practices required to grow Low-Carbon Grain,” said Amol Deshpande, CEO and Co-Founder of FBN. “With GRO Network, the efforts of farmers as well as food and feed companies, biofuel makers, and ordinary consumers to reduce carbon emissions just got a huge boost.”

Transparency in the agriculture supply chain starts with data direct from the field.

Farmers share information on their cultivation practices - including fertilizer applications, tillage, and cover cropping - with GRO Network, which is processed with artificial intelligence that leverage FBN’s 240 million acre-events of real world farm data, validates and distills the practices into a single farm-level score. This single score - which is the only information shared between GRO Network and prospective buyers - informs the buyer to then source premium grain as well as build programs to meet unique sustainability goals, while protecting farmers’ data privacy.

Importantly, verifiable Low-Carbon Grain will allow agricultural processors and food companies to meet their own significant emission goals. Policymakers will be able to evaluate a precise, farm-level carbon-intensity score to more accurately measure the GHG reduction of biofuels for low carbon fuel policies. GRO Network will help these companies embed the required carbon traceability into their supply chains, all within the current government policy framework.

“At POET we know that agriculture is the key to combating climate change, and we want to support farmers who share our mission to be good stewards of the earth by using environmentally friendly practices,” said POET Founder and CEO Jeff Broin. “We are excited about the potential of the GRO Network to promote sustainable agriculture and utilize the resulting Low-Carbon Corn to produce even greener bioethanol and bioproducts.”

GRO Network is focusing initially on carbon abatement, which, based on GRO Network pilots, can reduce grain emissions by up to 50%, while increasing farm revenues at the same time. It relies on proven, existing science and robust FBN analytics to measure the benefits of conservation activities on the farm, providing immediate, low-risk solutions to reduce the environmental impact of the agriculture supply chain.

“Regenerative agriculture techniques have not only saved us money, they’ve made us money,” said Todd Hanten, who farms 3,000 acres of corn, soybeans and spring wheat in South Dakota. “We’ve always tried these practices side by side and can compare conventional tillage to no-till and strip till and we’ve realized the benefits through our data analytics. We’re happy to find out that the practices we’ve adopted are saving us money and making us a better return.”

FBN began development of GRO Network close to two years ago in order to allow fuel, food and feed companies to work alongside farmers to accelerate the adoption of regenerative agricultural practices that deliver the biggest impact. GRO Network incentivizes sustainable conservation and soil health practices by producers, ensuring a consistent supply of high quality, Low-Carbon Grain for buyers.

“Ultimately, GRO Network aligns farmers, processors, brands, consumers and policy-makers in the fight against climate change,” Deshpande said. “We are excited to see family farm incomes improve as a direct result.”

Learn more at www.fbngro.com

About FBN:

Farmer’s Business Network, Inc. is an independent ag tech platform and farmer-to-farmer network with a mission to power the prosperity of family farmers around the world, while working towards a sustainable future. Its Farmers First® promise has attracted over 14,000 members to the network with a common goal of maximizing their farm’s profit potential. FBN has set out to redefine value and convenience for farmers by helping reduce the cost of production and maximize the value of their crops.

The FBN network has grown to cover more than 40 million acres of member farms in the U.S., Canada and Australia. Blending the best of Midwestern agricultural roots and Silicon Valley technology, the company has over 600 personnel and offices in San Carlos, Calif., Chicago, Sioux Falls, S.D., a Canadian headquarters in High River, Alta., and an Australian headquarters in Perth.

To learn more, visit: www.fbn.com.

Copyright ©2020 Farmer's Business Network, Inc. All rights reserved. The sprout logo, “Farmers Business Network”, “FBN”, “Farmers First” and the Farmers First flag logo are registered service marks of Farmer’s Business Network, Inc. All other marks are the property of their respective owners.

Copyright ©2020 GRO Network. All rights reserved. “GRO Network” and the GRO Network logo are registered trademarks of GRO Network.

Contact information

Media:
Keith Chapman
Chap Public Relations
Keith@chappublicrelations.com
847-970-2171

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom